These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 15042012)

  • 1. Is nuchal translucency screening associated with different rates of invasive testing in an older obstetric population?
    Chasen ST; McCullough LB; Chervenak FA
    Am J Obstet Gynecol; 2004 Mar; 190(3):769-74. PubMed ID: 15042012
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nuchal translucency and the acceptance of invasive prenatal chromosomal diagnosis in women aged 35 and older.
    Zoppi MA; Ibba RM; Putzolu M; Floris M; Monni G
    Obstet Gynecol; 2001 Jun; 97(6):916-20. PubMed ID: 11384696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Screening for trisomy 21 in twins using first trimester ultrasound and maternal serum biochemistry in a one-stop clinic: a review of three years experience.
    Spencer K; Nicolaides KH
    BJOG; 2003 Mar; 110(3):276-80. PubMed ID: 12628267
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sequential screening for trisomy 21 by nuchal translucency measurement in the first trimester and maternal serum biochemistry in the second trimester in a low-risk population.
    Schuchter K; Hafner E; Stangl G; Ogris E; Philipp K
    Ultrasound Obstet Gynecol; 2001 Jul; 18(1):23-5. PubMed ID: 11489220
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of maternal serum screening on the birth prevalence of Down's syndrome and the use of amniocentesis and chorionic villus sampling in South Australia.
    Cheffins T; Chan A; Haan EA; Ranieri E; Ryall RG; Keane RJ; Byron-Scott R; Scott H; Gjerde EM; Nguyen AM; Ford JH; Sykes S
    BJOG; 2000 Dec; 107(12):1453-9. PubMed ID: 11192100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fetal chromosomal abnormalities: antenatal screening and diagnosis.
    Anderson CL; Brown CE
    Am Fam Physician; 2009 Jan; 79(2):117-23. PubMed ID: 19178062
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Webbing of the neck and nasal bone--prenatal screening for Down syndrome].
    Svennekjaer S; Skibsted L
    Ugeskr Laeger; 2003 Apr; 165(17):1768-71. PubMed ID: 12768905
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased nuchal translucency as a marker for fetal chromosomal defects.
    Taipale P; Hiilesmaa V; Salonen R; Ylöstalo P
    N Engl J Med; 1997 Dec; 337(23):1654-8. PubMed ID: 9385124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison and integration of first trimester fetal nuchal translucency and second trimester maternal serum screening for fetal Down syndrome.
    Lam YH; Lee CP; Sin SY; Tang R; Wong HS; Wong SF; Fong DY; Tang MH; Woo HH
    Prenat Diagn; 2002 Aug; 22(8):730-5. PubMed ID: 12210586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnosis and management of fetal nuchal translucency.
    Jackson M; Rose NC
    Semin Roentgenol; 1998 Oct; 33(4):333-8. PubMed ID: 9800243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Invasive prenatal diagnostic practice in Denmark 1996 to 2006.
    Vestergaard CH; Lidegaard Ø; Tabor A
    Acta Obstet Gynecol Scand; 2009; 88(3):362-5. PubMed ID: 19172424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Utilization of available prenatal screening and diagnosis: effects of the California screen program.
    Blumenfeld YJ; Taylor J; Lee HC; Hudgins L; Sung JF; El-Sayed YY
    J Perinatol; 2012 Dec; 32(12):907-12. PubMed ID: 22402484
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Uptake of noninvasive prenatal testing at a large academic referral center.
    Larion S; Warsof SL; Romary L; Mlynarczyk M; Peleg D; Abuhamad AZ
    Am J Obstet Gynecol; 2014 Dec; 211(6):651.e1-7. PubMed ID: 24954652
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nuchal translucency screening: how do women actually utilize the results?
    Caughey AB; Musci TJ; Belluomini J; Main D; Otto C; Goldberg J
    Prenat Diagn; 2007 Feb; 27(2):119-23. PubMed ID: 17152116
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population-based trends in invasive prenatal diagnosis for ultrasound-based indications: two decades of change from 1994 to 2016.
    Lostchuck E; Poulton A; Halliday J; Hui L
    Ultrasound Obstet Gynecol; 2019 Apr; 53(4):503-511. PubMed ID: 29877030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Are age cutoffs still used to identify candidates for invasive testing for chromosomal abnormalities?
    Wasden SW; Adams BN; Chasen ST
    J Reprod Med; 2011; 56(3-4):113-6. PubMed ID: 21542527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Screening for Down syndrome using first-trimester ultrasound and second-trimester maternal serum markers in a low-risk population: a prospective longitudinal study.
    Audibert F; Dommergues M; Benattar C; Taieb J; Thalabard JC; Frydman R
    Ultrasound Obstet Gynecol; 2001 Jul; 18(1):26-31. PubMed ID: 11489221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SURUSS in perspective.
    Wald NJ; Rodeck C; Hackshaw AK; Rudnicka A
    BJOG; 2004 Jun; 111(6):521-31. PubMed ID: 15198778
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Screening for Down's syndrome by fetal nuchal translucency measurement in a general obstetric population.
    Pajkrt E; van Lith JM; Mol BW; Bleker OP; Bilardo CM
    Ultrasound Obstet Gynecol; 1998 Sep; 12(3):163-9. PubMed ID: 9793187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Significance of chromosome 22q11 analysis after detection of an increased first-trimester nuchal translucency.
    Hollis B; Mavrides E; Carvalho JS; Hill L; Dickinson V; Thilaganathan B
    Ultrasound Obstet Gynecol; 2001 Jul; 18(1):32-4. PubMed ID: 11489222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.